Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor

Seminars in Arthritis and Rheumatism

Volumn 46, Issue 3, 2016, Pages 261-271

  Charles Schoeman, Christina ^a   Wicker, Pierre ^b   Gonzalez Gay, Miguel A ^c   Boy, Mary ^d   Zuckerman, Andrea ^d   Soma, Koshika ^d   Geier, Jamie ^d   Kwok, Kenneth ^d   Riese, Richard ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PW Consulting LLC   (United States)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d PFIZER INC   (United States)

Author keywords

Cardiovascular; Rheumatoid arthritis; Safety; Tofacitinib

Indexed keywords

ADALIMUMAB; LIPID; METHOTREXATE; PLACEBO; TOFACITINIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; JANUS KINASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEART DEATH; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; CARDIOVASCULAR DISEASES; HEART FAILURE; HYPERLIPIDEMIAS; INCIDENCE; MORTALITY;

ARTHRITIS, RHEUMATOID; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS, PHASE III AS TOPIC; HEART FAILURE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INCIDENCE; JANUS KINASES; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIGLYCERIDES;

EID: 84997501359     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2016.05.014     Document Type: Article

References (59)

1. [1] Nicola, P.J., Crowson, C.S., Maradit-Kremers, H., Ballman, K.V., Roger, V.L., Jacobsen, S.J., et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum 54 (2006), 60–67.
2. [2] Solomon, D.H., Goodson, N.J., Katz, J.N., Weinblatt, M.E., Avorn, J., Setoguchi, S., et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 65 (2006), 1608–1612.
3. [3] Avina-Zubieta, J.A., Thomas, J., Sadatsafavi, M., Lehman, A.J., Lacaille, D., Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 71 (2012), 1524–1529.
4. [4] Bacon, P.A., Stevens, R.J., Carruthers, D.M., Young, S.P., Kitas, G.D., Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev 1 (2002), 338–347.
5. [5] Kremers, H.M., Crowson, C.S., Therneau, T.M., Roger, V.L., Gabriel, S.E., High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum 58 (2008), 2268–2274.
6. [6] del Rincon, I., Williams, K., Stern, M.P., Freeman, G.L., Escalante, A., High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44 (2001), 2737–2745.
7. [7] Crowson, C.S., Matteson, E.L., Roger, V.L., Therneau, T.M., Gabriel, S.E., Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 110 (2012), 420–424.
8. [8] Solomon, D.H., Karlson, E.W., Rimm, E.B., Cannuscio, C.C., Mandl, L.A., Manson, J.E., et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107 (2003), 1303–1307.
9. [9] Full, L.E., Ruisanchez, C., Monaco, C., The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther, 11, 2009, 217.
10. [10] Gabriel, S.E., Heart disease and rheumatoid arthritis: understanding the risks. Ann Rheum Dis 69:Suppl. 1 (2010), i61–i64.
11. [11] Solomon, D.H., Kremer, J., Curtis, J.R., Hochberg, M.C., Reed, G., Tsao, P., et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 69 (2010), 1920–1925.
12. [12] Gonzalez, A., Maradit, K.H., Crowson, C.S., Ballman, K.V., Roger, V.L., Jacobsen, S.J., et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?. Ann Rheum Dis 67 (2008), 64–69.
13. [13] Brady, S.R., de Court, Reid, C.M., Cicuttini, F.M., de Court, Liew, D., The role of traditional cardiovascular risk factors among patients with rheumatoid arthritis. J Rheumatol 36 (2009), 34–40.
14. [14] Maradit-Kremers, H., Nicola, P.J., Crowson, C.S., Ballman, K.V., Gabriel, S.E., Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52 (2005), 722–732.
15. [15] Solomon, D.H., Reed, G.W., Kremer, J.M., Curtis, J.R., Farkouh, M.E., Harrold, L.R., et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 67 (2015), 1449–1455.
16. [16] Barnabe, C., Martin, B.J., Ghali, W.A., Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 63 (2011), 522–529.
17. [17] Westlake, S.L., Colebatch, A.N., Baird, J., Curzen, N., Kiely, P., Quinn, M., et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 50 (2011), 518–531.
18. [18] Kremer, J.M., Bloom, B.J., Breedveld, F.C., Coombs, J.H., Fletcher, M.P., Gruben, D., et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60 (2009), 1895–1905.
19. [19] Tanaka, Y., Suzuki, M., Nakamura, H., Toyoizumi, S., Zwillich, S.H., Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 63 (2011), 1150–1158.
20. [20] Tanaka, Y., Takeuchi, T., Yamanaka, H., Suzuki, M., Nakamura, H., Toyoizumi, S., et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor, as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week phase 2b study. Arthritis Rheum 63:Suppl. 10 (2011), S844–S855 [abstract 2192].
21. [21] Fleischmann, R., Cutolo, M., Genovese, M.C., Lee, E.B., Kanik, K.S., Sadis, S., et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 64 (2012), 617–629.
22. [22] Kremer, J.M., Cohen, S., Wilkinson, B.E., Connell, C.A., French, J.L., Gomez-Reino, J., et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 64 (2012), 970–981.
23. [23] Burmester, G.R., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381 (2013), 451–460.
24. [24] Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C.A., Bradley, J.D., et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367 (2012), 495–507.
25. [25] Kremer, J., Li, Z.G., Hall, S., Fleischmann, R., Genovese, M., Martin-Mola, E., et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159 (2013), 253–261.
26. [26] Lee, E.B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J., Gruben, D., et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370 (2014), 2377–2386.
27. [27] van der Heijde, D., Tanaka, Y., Fleischmann, R., Keystone, E., Kremer, J., Zerbini, C., et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65 (2013), 559–570.
28. [28] van Vollenhoven, R.F., Fleischmann, R., Cohen, S., Lee, E.B., García Meijide, J.A., Wagner, S., et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367 (2012), 508–519.
29. [29] Wollenhaupt, J., Silverfield, J., Lee, E.B., Curtis, J.R., Wood, S.P., Soma, K., et al. Safety and efficacy of tofacitinib, an oral Janus kinase Inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 41 (2014), 837–852.
30. [30] Wollenhaupt, J., Silverfield, J., Lee, E.B., Wood, S.P., Terry, K., Nakamura, H., et al. Tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension over 6 years. Ann Rheum Dis, 74, 2015, 259.
31. [31] Tanaka, Y., Takeuchi, T., Yamanaka, H., Nakamura, H., Toyoizumi, S., Zwillich, S., Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, Phase 2 study. Mod Rheumatol 25 (2015), 514–521.
32. [32] Fukuyama, N., Homma, K., Wakana, N., Kudo, K., Suyama, A., Ohazama, H., et al. Validation of the Friedewald equation for evaluation of plasma LDL-cholesterol. J Clin Biochem Nutr 43 (2008), 1–5.
33. [33] Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L. Jr., et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42 (2003), 1206–1252.
34. [34] Watson, D.J., Rhodes, T., Guess, H.A., All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 30 (2003), 1196–1202.
35. [35] Jacobsson, L.T., Turesson, C., Gulfe, A., Kapetanovic, M.C., Petersson, I.F., Saxne, T., et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32 (2005), 1213–1218.
36. [36] Evans, M.R., Escalante, A., Battafarano, D.F., Freeman, G.L., O'Leary, D.H., del, R.I., Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. Arthritis Rheum 63 (2011), 1211–1220.
37. [37] NCEP A.T.P. III. National Cholesterol Education Program. ATP III Guidelines. 〈http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf〉 [accessed 2001].
38. [38] Micha, R., Imamura, F., Wyler von, B.M., Solomon, D.H., Hernan, M.A., Ridker, P.M., et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 108 (2011), 1362–1370.
39. [39] Westlake, S.L., Colebatch, A.N., Baird, J., Kiely, P., Quinn, M., Choy, E., et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 49 (2010), 295–307.
40. [40] Greenberg, J.D., Kremer, J.M., Curtis, J.R., Hochberg, M.C., Reed, G., Tsao, P., et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 70 (2011), 576–582.
41. [41] Bili, A., Tang, X., Pranesh, S., Bozaite, R., Morris, S.J., Antohe, J.L., et al. Tumor necrosis factor alpha inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 66 (2014), 355–363.
42. [42] Nurmohamed, M., Bao, Y., Signorovitch, J., Trahey, A., Mulani, P., Furst, D.E., Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis. RMD Open, 1, 2015, e000080.
43. [43] Roubille, C., Martel-Pelletier, J., Davy, J.M., Haraoui, B., Pelletier, J.P., Cardiovascular adverse effects of anti-inflammatory drugs. Antiinflamm Antiallergy Agents Med Chem 12 (2013), 55–67.
44. [44] Rao, V.U., Pavlov, A., Klearman, M., Musselman, D., Giles, J.T., Bathon, J.M., et al. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol 67 (2015), 372–380.
45. [45] Boers, M., Nurmohamed, M.T., Doelman, C.J., Lard, L.R., Verhoeven, A.C., Voskuyl, A.E., et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 62 (2003), 842–845.
46. [46] Choy, E., Sattar, N., Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68 (2009), 460–469.
47. [47] Jamnitski, A., Visman, I.M., Peters, M.J., Dijkmans, B.A., Voskuyl, A.E., Nurmohamed, M.T., Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study. Ann Rheum Dis 69 (2010), 1929–1933.
48. [48] Toms, T.E., Panoulas, V.F., Kitas, G.D., Dyslipidaemia in rheumatological autoimmune diseases. Open Cardiovasc Med J 5 (2011), 64–75.
49. [49] Curtis, J.R., John, A., Baser, O., Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-TNF therapy. Arthritis Care Res 64 (2012), 1282–1291.
50. [50] Peters, M.J., Symmons, D.P., McCarey, D., Dijkmans, B.A., Nicola, P., Kvien, T.K., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69 (2010), 325–331.
51. [51] Arts, E.E., Popa, C., den Broeder, A.A., Semb, A.G., Toms, T., Kitas, G.D., et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis 74 (2015), 668–674.
52. [52] Dessein, P.H., Semb, A.G., Could cardiovascular disease risk stratification and management in rheumatoid arthritis be enhanced?. Ann Rheum Dis 72 (2013), 1743–1746.
53. [53] Corrales, A., Gonzalez-Juanatey, C., Peiro, M.E., Blanco, R., Llorca, J., Gonzalez-Gay, M.A., Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis 73 (2014), 722–727.
54. [54] Charles-Schoeman, C., Fleischmann, R., Davignon, J., Schwartz, H., Turner, S.M., Beysen, C., et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol 67 (2015), 616–625.
55. [55] McInnes, I., Kaplan, I., Boy, M., Riese, R., Zuckerman, A., Gruben, D., et al. Effects of tofacitinib on lipid biomarkers in patients with active rheumatoid arthritis. Ann Rheum Dis, 72(Suppl. 3), 2013, 416.
56. [56] Charles-Schoeman, C., Lee, Y.Y., Shahbazian, A., Gorn, A.H., FitzGerald, J., Ranganath, V.K., et al. Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis. Arthritis Rheum 65 (2013), 2765–2772.
57. [57] McInnes, I.B., Thompson, L., Giles, J.T., Bathon, J.M., Salmon, J.E., Beaulieu, A.D., et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 74 (2015), 694–702.
58. [58] Popa, C., van Tits, L.J., Barrera, P., Lemmers, H.L., van den Hoogen, F.H., van Riel, P.L., et al. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis 68 (2009), 868–872.
59. [59] Arnett, F.C., Edworthy, S.M., Bloch, D.A., McShane, D.J., Fries, J.F., Cooper, N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988), 315–324.